Unused boxed Kit type A for the phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust, Stepping Hill Hospital, including participant self swab sample, in a black bag labelled NVX03446474 and biological substance category B UN3373 packaging, DCG Pathoseal® 95 bag, labelled 19033124, ruler, digital thermometer, model HK-901, made by Dong Guan City Good Health Electronic Technology Co Ltd, blood sampling vacutainer, known as Eclipse™ Blood Collection needle with pre attached holder, ref 368350, made by Beckton, Dickinson and Company, screw top tubes (white capped, labelled N-Protein 1, barcode 1JP29475946; red screw top labelled, N-Protein 2, barcode 1JP25544552, red push top, labelled Draw Tube, labelled N-Protein Coll, barcode 1JP25282506), clear plastic 3 ml pipette, blank study identification card (version 1.0 7 Sept 2020), sticker with PPD, notice “do not mix kits, and 3 requisition and contents sheet, 2020

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.